Tempest Therapeutics, Inc. (TPST): Submission of Matters to a Vote of Security Holders
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On September 15, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order
How this was made
The 30-second read
Why it matters
The amendment seeks to replace supermajority voting thresholds, potentially altering future merger or acquisition approvals.
Market read
Corporate governance filing with modest trading relevance; primarily of interest to existing shareholders.
What to watch
Potential proxy contest or activist involvement not disclosed in the filing.
Background
Tempest Therapeutics filed an 8‑K to disclose a reconvened special meeting for a shareholder vote on a charter amendment.
Ticker impact
SEC 8‑K filing announces reconvened special meeting to vote on amendment requiring 75% approval of stockholders.
Limited short‑term impact; price may stay flat unless vote outcome is unexpected.
The filing is a routine corporate action with no immediate financial consequence, but the amendment could influence future control dynamics.
Market effects
May signal governance tightening in biotech sector but unlikely to affect peers broadly.
US biotech market unaffected in the short term.
Low; limited to Tempest shareholders.
Counterpoint
If the amendment fails, it could trigger activist pressure and short‑term volatility.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm filing the proxy statement.
- service_providerSodali & Co.
Proxy solicitation firm assisting Tempest.
